Plexium

About:

Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.

Website: http://plexium.com

Twitter/X: plexiumtx

Top Investors: RA Capital Management, CRV, Biotechnology Value Fund, SoftBank Vision Fund, Lux Capital

Description:

Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases. Plexium's platform focuses on the discovery of next-generation TPD drugs that extend beyond the limited applications of Proteolysis Targeting Chimeras (PROTACs) and cereblon imids, unraveling the boundless possibilities of true drug-like protein degraders. From molecular glues to monovalent degraders, the possibilities are endless across a wide variety of therapeutic areas.

Total Funding Amount:

$165M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Diego, California, United States

Founded Date:

2018-01-01

Contact Email:

media(AT)plexium.com

Founders:

Andrew MacConnell, Joe Rokicki

Number of Employees:

51-100

Last Funding Date:

2022-02-23

IPO Status:

Private

Industries:

© 2025 bioDAO.ai